NAPSR news: Pfizer to Acquire InnoPharma, Inc. and Their Injectables Portfolio

WASHINGTON - July 17, 2014 - PRLog -- Pfizer announced yesterday its plans to acquire InnoPharma. In accordance with the agreement Pfizer is set to make upfront cash payment of $225 million and $135 million of provisional milestone payments for the acquisition.

With this acquisition, Pfizer will obtain InnoPharma’s current portfolio which includes 10 generic products approved by the FDA, the company’s 30 injectable products and opthalmic products in development along with 19 products filed with the FDA .

InnoPharma’s appeasing dynamic is due to the company’s main mission of researching and developing novel formulation of existing drugs including products with complex manufacturing processes in the areas of cancer and central nervous disorders. For instance, their pipeline consists of complex injectable delivery forms, pens and depot injectables along with the development of new dosage forms including oral suspensions and nasals.

“Today’s announcement is an important milestone as we continue to look for innovative growth opportunities for our sterile injectables portfolio, which will increase to seventy three products with this acquisition,” said John Young, group president, Pfizer Global Established Pharma (GEP). “InnoPharma’s technical capabilities in bringing complex generics to market, coupled with its strong talent and product pipeline, build on our efforts to develop and commercialize critically important medicines for the patients who need them.”

Upon completion of the acquisition, Pfizers new injectables portfolio will consist of 73 products and will include currently marketed products and the products filed with the FDA. Currently, Pfizer has a sterile injectable portfolio consisting of 44 products with over 190 presentations in the U.S

“InnoPharma has emerged as a strong development company over the years, with a portfolio of complex and differentiated products that provide value and options to patients and payors, and has an excellent team that has executed on this business model so successfully,” said Navneet Puri, PhD, President and CEO of InnoPharma. “We are very pleased to continue to provide this value as part of Pfizer, which has demonstrated its leadership within the pharmaceutical industry and a focus on improving patient health.”

The closing of this transaction is projected to happen during the third quarter upon US regulatory approval.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

With such industry leaders participating in various mergers and acquisitions – the projected gains in profitability will certainly add an impactful boost the healthcare market. This will without a doubt bolster the need for both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.